Rubius Therapeutics

$6.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.50 (+8.45%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RUBY and other stocks, options, and ETFs commission-free!

About RUBY

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA. The listed name for RUBY is Rubius Therapeutics, Inc. Common Stock.

CEO

Pablo J. Cagnoni

Employees

223

Headquarters

Cambridge, Massachusetts

Founded

2013

Market Cap

519.53M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

209.24K

High Today

$6.63

Low Today

$5.99

Open Price

$5.99

Volume

340.04K

52 Week High

$14.44

52 Week Low

$3.35

Collections

Analyst Ratings

50%

of 6 ratings

Buy

50%

Hold

33%

Sell

17%

RUBY Earnings

-$0.60

-$0.40

-$0.20

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, Pre-Market